bleeding score

Info. y referencias

CRUSADE cuantifica el riesgo de sangrado mayor intrahospitalario (Retroperitoneal o HIC, caida del Hto> 12%...) independientemente del tipo de tratamiento empleado, ayudándonos a establecer el riesgo de sangrado basal de los pacientes con SCASEST.

Referencia: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score.

The CRUSADE bleeding Score combines 8 readily available variables (baseline hematocrit, creatinine clearance, female sex, diabetes, peripheral vascular disease, signs of heart failure, systolic blood pressure, and heart rate on admission) into a validated bleeding risk Score (range 1 to 100 points). This Score stratifies baseline bleeding risk across quintiles: Very low risk (Score ≤20), low risk (21 to 30), moderate risk (31 to 40), high risk (41 to 50), and very high risk (≥50). In CRUSADE, observed rates of major in-hospital bleeding across quintiles of risk were 3.1% (very low risk), 5.5% (low risk), 8.6% (moderate risk), 11.9% (high risk), and 19.5% (very high risk). By providing an estimation of baseline risk of bleeding, application of the CRUSADE bleeding Score will better equip providers to consider the safety and efficacy implications of various treatment strategies for a patient with non–ST-segment elevation myocardial infarction.
Rate of major bleeding among patients treated with <2 vs ≥2 antithrombotic* drugs (across CRUSADE bleeding Score in the derivation cohort. * Antithrombotic defined as: antiplatelet(aspirin or clopidogrel), anticoagulant , GP IIb/IIIa.